Clinicians in two minds over atypical antipsychotics

Abstract

I t’s now almost a decade since Sandoz launched the first atypical antipsychotic (clozapine) in the UK and opened a new chapter in the history of schizophrenia management. A number of other atypicals followed. These undoubtedly offer clinical benefits in this devastating disease, especially for patients who either cannot tolerate, or do not respond to, older agents.